Advances in stroke therapy

Drug Delivery and Translational Research

Volumn 1, Issue 6, 2011, Pages 409-419

  Jaffer, Hayder ^a   Morris, Viola B ^a   Stewart, Desiree ^b   Labhasetwar, Vinod ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antioxidant enzymes; Blood brain barrier; Brain ischemia; Nanoparticles; Neuronal damage; Oxidative stress; Reactive oxygen species

Indexed keywords

4 PHOSPHONOMETHYLPIPECOLIC ACID; ACETYLSALICYLIC ACID; APTIGANEL; CALCIUM CHANNEL BLOCKING AGENT; CATALASE; DIPYRIDAMOLE; DISUFENTON SODIUM; ELIPRODIL; ENLIMOMAB; FLUNARIZINE; FOSPHENYTOIN SODIUM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NIMODIPINE; REACTIVE OXYGEN METABOLITE; ROVELIZUMAB; SUPEROXIDE DISMUTASE; TISSUE PLASMINOGEN ACTIVATOR; ZONAMPANEL;

BLEEDING; BLOOD BRAIN BARRIER; BLOOD CLOT LYSIS; BRAIN BLOOD FLOW; CRANIOTOMY; DECOMPRESSION SURGERY; DEVICES; DRUG MECHANISM; EMBOLECTOMY; HUMAN; MECHANICAL THROMBECTOMY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; STROKE;

EID: 84861227467     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-011-0046-y     Document Type: Review

References (88)

1. Hakim AM. Ischemic penumbra: the therapeutic window. Neurology. 1998; 51(3 Suppl 3): S44-6.
2. Jones TH, Morawetz RB, Crowell RM, Marcoux FW, FitzGibbon SJ, DeGirolami U, et al. Thresholds of focal cerebral ischemia in awake monkeys. J Neurosurg. 1981; 54(6): 773-82.
3. Ostrowski RP, Colohan AR, Zhang JH. Molecular mechanisms of early brain injury after subarachnoid hemorrhage. Neurol Res. 2006; 28(4): 399-414.
4. Jean WC, Spellman SR, Nussbaum ES, Low WC. Reperfusion injury after focal cerebral ischemia: the role of inflammation and the therapeutic horizon. Neurosurgery. 1998; 43(6): 1382-96.
5. Siesjo BK, Agardh CD, Bengtsson F. Free radicals and brain damage. Cerebrovasc Brain Metab Rev. 1989; 1(3): 165-211.
6. Hademenos GJ, Massoud TF. Biophysical mechanisms of stroke. Stroke. 1997; 28(10): 2067-77.
7. Garcia JH, Liu KF, Yoshida Y, Lian J, Chen S, del Zoppo GJ. Influx of leukocytes and platelets in an evolving brain infarct (Wistar rat). Am J Pathol. 1994; 144(1): 188-99.
8. Siesjo BK. Cell damage in the brain: a speculative synthesis. J Cereb Blood Flow Metab. 1981; 1(2): 155-85.
9. Becker KJ. Inflammation and acute stroke. Curr Opin Neurol. 1998; 11(1): 45-9.
10. Cuzzocrea S, Riley DP, Caputi AP, Salvemini D. Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol Rev. 2001; 53(1): 135-59.
11. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007; 39(1): 44-84.
12. Janardhan V, Qureshi AI. Mechanisms of ischemic brain injury. Curr Cardiol Rep. 2004; 6(2): 117-23.
13. Haddad JJ. Redox regulation of pro-inflammatory cytokines and IkappaB-alpha/NF-kappaB nuclear translocation and activation. Biochem Biophys Res Commun. 2002; 296(4): 847-56.
14. Cao W, Carney JM, Duchon A, Floyd RA, Chevion M. Oxygen free radical involvement in ischemia and reperfusion injury to brain. Neurosci Lett. 1988; 88(2): 233-8.
15. Juurlink BH, Sweeney MI. Mechanisms that result in damage during and following cerebral ischemia. Neurosci Biobehav Rev. 1997; 21(2): 121-8.
16. Wagner KR, Jauch EC. Extending the window for acute stroke treatment: thrombolytics plus CNS protective therapies. Exp Neurol. 2004; 188(2): 195-9.
17. Fisher M. The ischemic penumbra: identification, evolution and treatment concepts. Cerebrovasc Dis. 2004; 17 Suppl 1: 1-6.
18. Turner R, Vink R. Inhibition of neurogenic inflammation as a novel treatment for ischemic stroke. Timely Top Med Cardiovasc Dis. 2007; 11: E24.
19. Bambauer KZ, Johnston SC, Bambauer DE, Zivin JA. Reasons why few patients with acute stroke receive tissue plasminogen activator. Arch Neurol. 2006; 63(5): 661-4.
20. Su EJ, Fredriksson L, Geyer M, Folestad E, Cale J, Andrae J, et al. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med. 2008; 14(7): 731-7.
21. Yepes M, Sandkvist M, Moore EG, Bugge TH, Strickland DK, Lawrence DA. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest. 2003; 112(10): 1533-40.
22. Goto H, Fujisawa H, Oka F, Nomura S, Kajiwara K, Kato S, et al. Neurotoxic effects of exogenous recombinant tissue-type plasminogen activator on the normal rat brain. J Neurotrauma. 2007; 24(4): 745-52.
23. Zaidat OO, Suarez JI, Santillan C, Sunshine JL, Tarr RW, Paras VH, et al. Response to intra-arterial and combined intravenous and intra-arterial thrombolytic therapy in patients with distal internal carotid artery occlusion. Stroke. 2002; 33(7): 1821-6.
24. Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke. 2007; 38(3): 967-73.
25. Nogueira RG, Yoo AJ, Buonanno FS, Hirsch JA. Endovascular approaches to acute stroke, part 2: a comprehensive review of studies and trials. AJNR. 2009; 30(5): 859-75.
26. Lewandowski CA, Frankel M, Tomsick TA, Broderick J, Frey J, Clark W, et al. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke. 1999; 30(12): 2598-605.
27. The Interventional Management of Stroke (IMS) II Study. Stroke. 2007; 38(7): 2127-35.
28. Smith WS. Safety of mechanical thrombectomy and intravenous tissue plasminogen activator in acute ischemic stroke. Results of the multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial, part I. AJNR. 2006; 27(6): 1177-82.
29. Smith WS, Sung G, Saver J, Budzik R, Duckwiler G, Liebeskind DS, et al. Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. Stroke. 2008; 39(4): 1205-12.
30. Brekenfeld C, Schroth G, El-Koussy M, Nedeltchev K, Reinert M, Slotboom J, et al. Mechanical thromboembolectomy for acute ischemic stroke: comparison of the catch thrombectomy device and the Merci Retriever in vivo. Stroke. 2008; 39(4): 1213-9.
31. Liebig T, Reinartz J, Hannes R, Miloslavski E, Henkes H. Comparative in vitro study of five mechanical embolectomy systems: effectiveness of clot removal and risk of distal embolization. Neuroradiology. 2008; 50(1): 43-52.
32. Natarajan SK, Snyder KV, Siddiqui AH, Ionita CC, Hopkins LN, Levy EI. Safety and effectiveness of endovascular therapy after 8 hours of acute ischemic stroke onset and wake-up strokes. Stroke. 2009; 40(10): 3269-74.
33. The Penumbra Pivotal Stroke Trial. safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. Stroke. 2009; 40(8): 2761-8.
34. Struffert T, Kohrmann M, Engelhorn T, Nowe T, Richter G, Schellinger PD, et al. Penumbra Stroke System as an "add-on" for the treatment of large vessel occlusive disease following thrombolysis: first results. Eur Radiol. 2009; 19(9): 2286-93.
35. Nogueira RG, Schwamm LH, Hirsch JA. Endovascular approaches to acute stroke, part 1: drugs, devices, and data. AJNR. 2009; 30(4): 649-61.
36. Abou-Chebl A, Bajzer CT, Krieger DW, Furlan AJ, Yadav JS. Multimodal therapy for the treatment of severe ischemic stroke combining GPIIb/IIIa antagonists and angioplasty after failure of thrombolysis. Stroke. 2005; 36(10): 2286-8.
37. Levy EI, Siddiqui AH, Crumlish A, Snyder KV, Hauck EF, Fiorella DJ, et al. First Food and Drug Administration-approved prospective trial of primary intracranial stenting for acute stroke: SARIS (stent-assisted recanalization in acute ischemic stroke). Stroke. 2009; 40(11): 3552-6.
38. Jahan R. Solitaire flow-restoration device for treatment of acute ischemic stroke: safety and recanalization efficacy study in a swine vessel occlusion model. AJNR. 2010; 31(10): 1938-43.
39. Hofmeijer J, Schepers J, Veldhuis WB, Nicolay K, Kappelle LJ, Bar PR, et al. Delayed decompressive surgery increases apparent diffusion coefficient and improves peri-infarct perfusion in rats with space-occupying cerebral infarction. Stroke. 2004; 35(6): 1476-81.
40. Hacke W, Schwab S, Horn M, Spranger M, De Georgia M, von Kummer R. 'Malignant' middle cerebral artery territory infarction: clinical course and prognostic signs. Arch Neurol. 1996; 53(4): 309-15.
41. Adams Jr HP, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke. 2007; 38(5): 1655-711.
42. Schwab S, Steiner T, Aschoff A, Schwarz S, Steiner HH, Jansen O, et al. Early hemicraniectomy in patients with complete middle cerebral artery infarction. Stroke. 1998; 29(9): 1888-93.
43. Adibhatla RM, Hatcher JF. Altered lipid metabolism in brain injury and disorders. Subcell Biochem. 2008; 49: 241-68.
44. Adibhatla RM, Hatcher JF. Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies. CNS Neurol Disord Drug Targets. 2008; 7(3): 243-53.
45. Margaill I, Plotkine M, Lerouet D. Antioxidant strategies in the treatment of stroke. Free Radic Biol Med. 2005; 39(4): 429-43.
46. Francis JW, Ren J, Warren L, Brown Jr RH, Finklestein SP. Postischemic infusion of Cu/Zn superoxide dismutase or SOD: Tet451 reduces cerebral infarction following focal ischemia/reperfusion in rats. Exp Neurol. 1997; 146(2): 435-43.
47. Schaller B, Graf R. Cerebral ischemia and reperfusion: the pathophysiologic concept as a basis for clinical therapy. J Cereb Blood Flow Metab. 2004; 24(4): 351-71.
48. Forsman M, Fleischer JE, Milde JH, Steen PA, Michenfelder JD. Superoxide dismutase and catalase failed to improve neurologic outcome after complete cerebral ischemia in the dog. Acta Anaesthesiol Scand. 1988; 32(2): 152-5.
49. Schurer L, Grogaard B, Gerdin B, Arfors KE. Superoxide dismutase does not prevent delayed hypoperfusion after incomplete cerebral ischaemia in the rat. Acta Neurochir (Wien). 1990; 103(3-4): 163-70.
50. Tsubokawa T, Jadhav V, Solaroglu I, Shiokawa Y, Konishi Y, Zhang JH. Lecithinized superoxide dismutase improves outcomes and attenuates focal cerebral ischemic injury via antiapoptotic mechanisms in rats. Stroke. 2007; 38(3): 1057-62.
51. Kim DW, Eum WS, Jang SH, Kim SY, Choi HS, Choi SH, et al. Transduced Tat-SOD fusion protein protects against ischemic brain injury. Mol Cells. 2005; 19(1): 88-96.
52. Veronese FM, Caliceti P, Schiavon O, Sergi M. Polyethylene glycol-superoxide dismutase, a conjugate in search of exploitation. Adv Drug Deliv Rev. 2002; 54(4): 587-606.
53. Morris MC, Depollier J, Mery J, Heitz F, Divita G. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol. 2001; 19(12): 1173-6.
54. Imaizumi S, Woolworth V, Fishman RA, Chan PH. Liposome-entrapped superoxide dismutase reduces cerebral infarction in cerebral ischemia in rats. Stroke. 1990; 21(9): 1312-7.
55. Sinha J, Das N, Basu MK. Liposomal antioxidants in combating ischemia-reperfusion injury in rat brain. Biomed Pharmacother. 2001; 55(5): 264-71.
56. Reddy MK, Wu L, Kou W, Ghorpade A, Labhasetwar V. Superoxide dismutase-loaded PLGA nanoparticles protect cultured human neurons under oxidative stress. Appl Biochem Biotechnol. 2008; 151(2-3): 565-77.
57. Reddy MK, Labhasetwar V. Nanoparticle-mediated delivery of superoxide dismutase to the brain: an effective strategy to reduce ischemia-reperfusion injury. FASEB J. 2009; 23(5): 1384-95.
58. Rosenberg GA, Yang Y. Vasogenic edema due to tight junction disruption by matrix metalloproteinases in cerebral ischemia. Neurosurg Focus. 2007; 22(5): E4.
59. Kuroda S, Siesjo BK. Reperfusion damage following focal ischemia: pathophysiology and therapeutic windows. Clin Neurosci. 1997; 4(4): 199-212.
60. Yasui K, Baba A. Therapeutic potential of superoxide dismutase (SOD) for resolution of inflammation. Inflammation Res. 2006; 55(9): 359-63.
61. Zhang Z, Zhang RL, Jiang Q, Raman SB, Cantwell L, Chopp M. A new rat model of thrombotic focal cerebral ischemia. J Cereb Blood Flow Metab. 1997; 17(2): 123-35.
62. Habeck M. New stroke therapies-hope for the future. Drug Discov Today. 2002; 7(3): 157-9.
63. Green AR, Shuaib A. Therapeutic strategies for the treatment of stroke. Drug Discov Today. 2006; 11(1516): 681-93.
64. Guyot LL, Diaz FG, O'Regan MH, McLeod S, Park H, Phillis JW. Real-time measurement of glutamate release from the ischemic penumbra of the rat cerebral cortex using a focal middle cerebral artery occlusion model. Neurosci Lett. 2001; 299(1-2): 37-40.
65. Boast CA, Gerhardt SC, Pastor G, Lehmann J, Etienne PE, Liebman JM. The N-methyl-d-aspartate antagonists CGS 19755 and CPP reduce ischemic brain damage in gerbils. Brain Res. 1988; 442(2): 345-8.
66. Gotti B, Duverger D, Bertin J, Carter C, Dupont R, Frost J, et al. Ifenprodil and SL 82. 0715 as cerebral anti-ischemic agents. I. Evidence for efficacy in models of focal cerebral ischemia. J Pharmacol Exp Ther. 1988; 247(3): 1211-21.
67. Aronowski J, Ostrow P, Samways E, Strong R, Zivin JA, Grotta JC. Graded bioassay for demonstration of brain rescue from experimental acute ischemia in rats. Stroke. 1994; 25(11): 2235-40.
68. Horn J, Limburg M. Calcium antagonists for acute ischemic stroke. Cochrane Database Syst Rev. 2000; 2: CD001928.
69. Noh SJ, Lee JM, Lee KS, Hong HS, Lee CK, Cho IH, et al. SP-8203 shows neuroprotective effects and improves cognitive impairment in ischemic brain injury through NMDA receptor. Pharmacol Biochem Behav. 2011; 100(1): 73-80.
70. Leker RR, Shohami E. Cerebral ischemia and trauma-different etiologies yet similar mechanisms: neuroprotective opportunities. Brain Res Brain Res Rev. 2002; 39(1): 55-73.
71. Feuerstein GZ, Zaleska MM, Krams M, Wang X, Day M, Rutkowski JL, et al. Missing steps in the STAIR case: a Translational Medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke. J Cereb Blood Flow Metab. 2008; 28(1): 217-9.
72. Saver JL, Kidwell C, Eckstein M, Starkman S. Prehospital neuroprotective therapy for acute stroke: results of the Field Administration of Stroke Therapy-Magnesium (FAST-MAG) pilot trial. Stroke. 2004; 35(5): e106-8.
73. Albers GW, Goldstein LB, Hess DC, Wechsler LR, Furie KL, Gorelick PB, et al. Stroke Treatment Academic Industry Roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies. Stroke. 2011; 42(9): 2645-50.
74. Deb P, Sharma S, Hassan KM. Pathophysiologic mechanisms of acute ischemic stroke: An overview with emphasis on therapeutic significance beyond thrombolysis. Pathophysiology. 2010; 17(3): 197-218.
75. Gedikli O, Baykan M. Statins in stroke prevention. Anadolu Kardiyol Derg. 2008; 8(3): 217-22.
76. Cheng YD, Al-Khoury L, Zivin JA. Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx. 2004; 1(1): 36-45.
77. Shintani Y, Terao Y, Ohta H. Molecular mechanisms underlying hypothermia-induced neuroprotection. Stroke Res Treat. 2011. doi: 10. 4061/2011/809874.
78. Lundbye JB, Rai M, Ramu B, Hosseini-Khalili A, Li D, Slim HB, et al. Therapeutic hypothermia is associated with improved neurologic outcome and survival in cardiac arrest survivors of non-shockable rhythms. Resuscitation. 2011 (in press).
79. Jacobs SE, Morley CJ, Inder TE, Stewart MJ, Smith KR, McNamara PJ, et al. Whole-body hypothermia for term and near-term newborns with hypoxic-ischemic encephalopathy: a randomized controlled trial. Arch Pediatr Adolesc Med. 2011; 165(8): 692-700.
80. Hemmen TM, Raman R, Guluma KZ, Meyer BC, Gomes JA, Cruz-Flores S, et al. Intravenous thrombolysis plus hypothermia for acute treatment of ischemic stroke (ICTuS-L): final results. Stroke. 2010; 41(10): 2265-70.
81. Ohta K, Graf R, Rosner G, Heiss WD. Calcium ion transients in peri-infarct depolarizations may deteriorate ion homeostasis and expand infarction in focal cerebral ischemia in cats. Stroke. 2001; 32(2): 535-43.
82. Gribkoff VK, Starrett Jr JE, Dworetzky SI, Hewawasam P, Boissard CG, Cook DA, et al. Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels. Nat Med. 2001; 7(4): 471-7.
83. Cheng Y, Deshmukh M, D'Costa A, Demaro JA, Gidday JM, Shah A, et al. Caspase inhibitor affords neuroprotection with delayed administration in a rat model of neonatal hypoxic-ischemic brain injury. J Clin Invest. 1998; 101(9): 1992-9.
84. Endres M, Namura S, Shimizu-Sasamata M, Waeber C, Zhang L, Gomez-Isla T, et al. Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family. J Cereb Blood Flow Metab. 1998; 18(3): 238-47.
85. Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke. 2009; 40(12): e647-56.
86. Wiltrout C, Lang B, Yan Y, Dempsey RJ, Vemuganti R. Repairing brain after stroke: a review on post-ischemic neurogenesis. Neurochem Int. 2007; 50(7-8): 1028-41.
87. Kennea NL, Mehmet H. Neural stem cells. J Pathol. 2002; 197(4): 536-50.
88. Roitberg B. Transplantation for stroke. Neurol Res. 2004; 26(3): 256-64.